Want to see GB:GENI full AI Analyst Report?
Top Page
GENinCode UK Ltd.
(LSE:GENI)
Select Model
Select Model
Rating:40Underperform
Price Target:
0.59 p
▼(-34.00% Downside)
Action:Downgraded
Date:09/30/26
The score is primarily held down by weak financial performance—deep unprofitability, ongoing cash burn, and a sharp decline in equity that increases balance-sheet risk. Technicals also remain bearish with the stock below major moving averages and negative MACD, despite oversold RSI. Valuation contributes only modestly given the negative P/E and lack of dividend yield.
Positive Factors
Revenue Growth Acceleration
The acceleration in revenue growth indicates improving commercial traction and expanding demand for the company’s diagnostic offerings. If sustained, stronger sales can increase operating leverage, support investment in the platform, and gradually improve the economics of the business over coming quarters.
Negative Factors
Deep and Widening Unprofitability
The scale of losses shows that current revenue is not sufficient to cover the company’s cost base, making profitability dependent on substantial operating improvement. Persistent negative EBIT and EBITDA also indicate that losses are rooted in core operations, increasing the risk of further funding needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Acceleration
The acceleration in revenue growth indicates improving commercial traction and expanding demand for the company’s diagnostic offerings. If sustained, stronger sales can increase operating leverage, support investment in the platform, and gradually improve the economics of the business over coming quarters.
Read all positive factors
GENinCode UK Ltd. (GENI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£4.71M
Dividend YieldN/A
Average Volume (3M)3.35M
Price to Earnings (P/E)―
Beta (1Y)-0.32
Revenue Growth-10.81%
EPS Growth42.67%
CountryUK
Employees44
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.01
Shares Outstanding753,041,140
10 Day Avg. Volume3,411,088
30 Day Avg. Volume3,352,751
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)53.10
Price to Sales (P/S)2.14
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.70M
GENinCode UK Ltd. Business Overview & Revenue Model
Company Description
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technolo...
GENinCode UK Ltd. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
35
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.60M | 3.08M | 2.70M | 2.16M | 1.43M | 1.15M |
| Gross Profit | 1.32M | 1.54M | 1.43M | 1.02M | 632.00K | 593.00K |
| EBITDA | -5.77M | -5.63M | -4.69M | -6.65M | -5.57M | -4.10M |
| Net Income | -5.26M | -5.71M | -4.43M | -7.02M | -5.56M | -4.14M |
Balance Sheet | ||||||
| Total Assets | 3.53M | 2.38M | 2.66M | 4.19M | 11.80M | 15.21M |
| Cash, Cash Equivalents and Short-Term Investments | 2.05M | 895.00K | 1.17M | 2.53M | 9.75M | 14.56M |
| Total Debt | 98.00K | 146.00K | 234.00K | 299.00K | 354.00K | 0.00 |
| Total Liabilities | 1.47M | 2.25M | 1.54M | 2.90M | 3.90M | 1.49M |
| Stockholders Equity | 2.06M | 124.00K | 1.13M | 1.29M | 7.90M | 13.72M |
Cash Flow | ||||||
| Free Cash Flow | -3.96M | -4.11M | -5.22M | -7.54M | -4.61M | -3.17M |
| Operating Cash Flow | -3.91M | -4.07M | -5.17M | -7.51M | -3.76M | -3.02M |
| Investing Cash Flow | -48.00K | -44.00K | 50.00K | 136.00K | -849.00K | -145.00K |
| Financing Cash Flow | 4.21M | 3.64M | 3.65M | -94.00K | -47.00K | 15.86M |
GENinCode UK Ltd. Technical Analysis
Negative
0.90
Price Trends
0.86
Negative
0.89
Negative
1.10
Negative
Market Momentum
-0.07
Positive
22.32
Positive
10.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GENI, the sentiment is Negative. The current price of 0.9 is above the 20-day moving average (MA) of 0.78, above the 50-day MA of 0.86, and below the 200-day MA of 1.10, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 22.32 is Positive, neither overbought nor oversold. The STOCH value of 10.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GENI.
GENinCode UK Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £27.17M | -12.80 | -55.91% | ― | 40.37% | -13.70% | |
49 Neutral | £18.46M | -1.06 | -1044.57% | ― | 65.60% | 74.84% | |
48 Neutral | £9.66M | -0.49 | -104.73% | ― | -56.10% | 41.10% | |
40 Underperform | £4.71M | -0.47 | -481.34% | ― | -10.81% | 42.67% | |
40 Underperform | £13.44M | -0.25 | -451.74% | ― | 33.37% | 86.41% | |
40 Underperform | £35.53M | -0.33 | -631.25% | ― | ― | ― |
* Healthcare Sector Average
GB:GENI
GENinCode UK Ltd.
0.63
-2.98
-82.64%
GB:CLBX
ANGLE plc
0.85
-1.05
-55.26%
GB:GDR
Genedrive
1.15
0.81
242.26%
GB:OBD
Oxford BioDynamics
0.10
-0.42
-80.77%
GB:RENX
Renalytix
5.30
-3.70
-41.11%
GB:ABDX
Abingdon Health PLC
10.75
4.70
77.69%
GENinCode UK Ltd. Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
GENinCode narrows losses as it advances global rollout of genetic heart and ovarian cancer tests
Neutral
Sep 29, 2026
GENinCode reported interim revenue of £1.1m for the six months to 30 June 2026, down from £1.6m a year earlier, as NHS cutbacks and the absence of prior-year Catalonia pilot income weighed on sales. Adjusted EBITDA losses narrowed to ...
Business Operations and StrategyFinancial Disclosures
GENinCode sets date for interim results as genetic risk platform gains strategic momentum
Positive
Sep 22, 2026
GENinCode Plc will publish its unaudited interim results for the six months ended 30 June 2026 on 29 September 2026, and has scheduled a briefing for equity research analysts that morning in Oxford. The update underscores the company’s progr...
Business Operations and StrategyFinancial Disclosures
GENinCode to unveil interim results as genetic risk tools gain clinical traction
Positive
Sep 22, 2026
GENinCode will publish its unaudited interim results for the six months to 30 June 2026 on 29 September 2026 and is hosting an analyst briefing the same day in Oxford, underscoring its engagement with the investment community. The announcement hig...
Business Operations and StrategyProduct-Related Announcements
GENinCode Pilot Backs Genetic Scoring for Coronary Risk in Primary Care
Positive
Aug 28, 2026
GENinCode reported preliminary real-world data from a Catalan primary care pilot showing its CARDIO inCode-Score polygenic risk test significantly refines coronary artery disease risk classification in moderate-risk patients. The study of 584 adul...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.